Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zimmer Will Seek Compensation From St. Gobain For Revision Surgery

This article was originally published in The Gray Sheet

Executive Summary

Zimmer will pay non-reimbursed direct medical costs associated with revision surgery for patients who were implanted with certain recalled Saint Gobain Advanced Ceramic Desmarquest zirconia ceramic femoral heads distributed by the Warsaw, Indiana-based firm

You may also be interested in...



FDA Warning Letter Urges St. Gobain To Get Hip To QSR Regs

Saint Gobain Advanced Ceramics Desmarquest did not adaquately verify and validate changes it made to its manufacturing process in 1998, FDA asserts in a recent warning letter outlining quality system reg (QSR) deficiencies related to certain artificial hip components

FDA Warning Letter Urges St. Gobain To Get Hip To QSR Regs

Saint Gobain Advanced Ceramics Desmarquest did not adaquately verify and validate changes it made to its manufacturing process in 1998, FDA asserts in a recent warning letter outlining quality system reg (QSR) deficiencies related to certain artificial hip components

French Health Authority Sparks Worldwide Recall of Zirconia Femoral Heads

The United Kingdom and Australia have issued device alert notices regarding the recall of Saint Gobain Advanced Ceramics Desmarquest zirconia ceramic femoral heads, following an Aug. 10 decision by the French government to suspend production and recall nine batches of the prosthetic hip components.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel